Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Background: The phase III trials CheckMate 017 (NCT01642004) and CheckMate 057 (NCT01673867) demonstrated improved OS with the anti-programmed death (PD)-1 antibody nivo vs doc as treatment (tx) for adv previously treated squamous (SQ) and non-SQ (NSQ) NSCLC, respectively. Approval of nivo in these indications was based on results of these studies. Updated results based on a minimum follow-up (f/u) of 2 y are reported.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
